Tuvusertib

AI-Designed Dual ATR-mTOR Inhibitor Demonstrates In Vivo Efficacy; Novel LNP Formulation of Bifunctional PARP/HDAC Inhibitor kt-3283 Successfully Characterized VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced the presentation of new preclinical data from two of its lead programs at the 2026 American Association for Cancer Research (AACR) Annual Meeting, held April 17–22 in San Diego, California. The data, presented across two poster sessions at the world’s premier cancer research forum, advance Rakovina’s AI-driven pipeline targeting DNA damage response (DDR) vulnerabilities in hard-to-treat solid tumors. Both programs leverage generative AI platforms to address longstanding limitations of existing cancer therapies, including poor central nervous system (CNS) penetrance and the toxicity burden of drug combination regimens. Novel Brain-Penetrant Dual ATR-mTOR Inhibitor Demonstrates In Vivo Efficacy in PTEN-Deficient Cancers The first poster, titled A Novel Brain-Penetrant Dual ATR-mTOR Inhibitor for PTEN-Deficient Cancers (Presentation #1743, DNA Damage and Repair 2 session, April 20), presented preclinical data from Rakovina’s program to develop first-in-class CNS-penetrating molecules that simultaneously inhibit ATR and mTOR, two key drivers of survival in PTEN-deficient cancer cells. The program was developed in collaboration with Variational AI (Vancouver, BC) using the Enki™ generative AI platform. PTEN deficiency is found in up to 40% of gliomas and 63% of breast cancers, which frequently metastasize to the brain. Simultaneous inhibition of ATR and mTOR is a rational therapeutic strategy in PTEN-deficient tumors, as PTEN loss activates both ATR-dependent DNA damage signaling and mTOR-driven cell survival pathways. However, no approved therapy directly addresses this dual vulnerability with effective CNS penetrance. Using the Enki™ latent diffusion model to simultaneously optimize potency, selectivity, CNS penetrance, and ADMET properties, Rakovina generated and synthesized a curated set of novel small-molecule dual ATR-mTOR inhibitor candidates. Key findings presented at AACR 2026 include: Enzymatic potency: Candidate compounds demonstrated equal or greater inhibition of recombinant ATR and mTOR enzymes compared to reference compounds ceralasertib and tuvusertib. Selectivity: Candidates are equally or more selective against PIKK family enzymes than the reference compounds ceralasertib and tuvusertib. Cell viability inhibition: Candidates inhibit cell viability of D283 medulloblastoma cells equally or more than reference compounds. A prototype lead candidate inhibited cell viability of both PTEN wild-type and PTEN-deficient cancer cell lines. Metabolic stability: After 45 minutes of incubation with human liver microsomes, candidate compounds demonstrated strong metabolic stability. CNS penetrance: Pharmacokinetic profiling following intraperitoneal administration in mice confirmed varying but measurable levels of CNS penetrance across candidates, with brain-to-plasma ratios broadly consistent with Enki™ AI predictions. In vivo efficacy: In a subcutaneous LNCaP prostate tumor model, a prototype lead candidate significantly prolonged tumor doubling time compared to vehicle control, with equal potency to reference compound ceralasertib. Critically, the Rakovina candidate was better tolerated than ceralasertib, demonstrating less weight loss with daily dosing and no signs of hematological toxicity at terminal complete blood count analysis. Optimization of candidate inhibitors is ongoing. Novel AI-Designed Lipid Nanoparticle Formulation of kt-3283 Successfully Characterized The second poster, titled Development of a Lipid Nanoparticle Formulation of the Bifunctional PARP and HDAC Inhibitor Kt-3283 (Presentation #6373, Drug Delivery session, April 21), presented preclinical formulation data on pLNP/kt-3283, developed in collaboration with NanoPalm (Riyadh, Saudi Arabia) using the EnsaliX AI platform. kt-3283 integrates PARP inhibition and HDAC-mediated chromatin remodeling into a single compound, thereby improving the PARP efficacy, and eliminating the need for combination drug regimens and their associated toxicity risks. While kt-3283 has demonstrated potent anti-tumor activity across multiple tumor types in prior in vitro studies, its clinical viability has been limited by bioavailability and metabolic stability challenges. The pLNP formulation has been specifically designed to address these limitations. Data presented confirm the successful assembly of the EnsaliX-designed patterned lipid nanoparticles. Physicochemical characterization confirmed uniform particle size, stable colloidal behavior, and a structured surface texture predicted to enhance cellular uptake. The pLNP/kt-3283 formulation demonstrated structure and particle size consistency supporting further biological evaluation. Next steps include in vitro and in vivo characterization to confirm activity against PARP and HDAC enzymes, determine ADME properties, and evaluate efficacy in tumor models. “Presenting at AACR is a meaningful milestone for our team, and these results represent a genuine step forward for both programs,” said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics. “The in vivo efficacy data for our ATR-mTOR inhibitor are particularly encouraging. The compound demonstrated potency comparable to an established reference compound while exhibiting a meaningfully improved tolerability profile. That is exactly the differentiation we are building toward. Combined with the initial characterization of our LNP formulation for kt-3283, we believe these results reinforce the potential of our AI-driven pipeline and support a path toward IND-enabling studies.” Rakovina’s AI-powered discovery approach leverages generative AI platforms to evaluate billions of potential drug candidates at a pace not achievable through traditional methods. These capabilities are supported by the company’s access to the University of British Columbia’s lab infrastructure, enabling rapid in-house testing of lead compounds. “These results demonstrate that our strategy of integrating AI-guided design with biological validation, is working as intended,” said Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. “For the ATR-mTOR program, our candidate inhibitors are tracking closely with the AI predictions for potency, selectivity, and CNS penetrance and our in vivo results give confidence in the direction of this program. For kt-3283, we have demonstrated that the EnsaliX-designed LNP formulation produces a well-characterized nanoparticle. The structured surface and organized phospholipid assembly we observed are precisely the properties expected to enhance nanoparticle stability and cellular uptake of kt-3283. Both programs have clear next steps, and we are moving forward with purpose.” The data presented at AACR 2026 reinforce the progress of Rakovina’s AI-enabled DDR inhibitor pipeline and inform the next phase of preclinical development for both programs. For the ATR-mTOR program, further optimization of candidate inhibitors is ongoing. For the kt-3283 LNP program, the company will advance in vitro and in vivo studies to further characterize biological activity prior to evaluating efficacy in tumor models. Rakovina intends to use these findings to advance best-in-class lead candidates toward IND-enabling studies in collaboration with pharmaceutical partners. About Rakovina Therapeutics Inc. Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using validated, proprietary platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at . Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Rakovina Therapeutics Forward-Looking Statements: This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “is expected,” “expects,” “scheduled,” “intends,” “contemplates,” “anticipates,” “believes,” “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the biopharmaceutical industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company’s most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company’s pro at For Further Information Contact: Investor Relations Rakovina Therapeutics Inc. IR@rakovinatherapeutics.com

1. 行业背景：同源重组修复缺陷与第一代PARP抑制剂的局限性       在过去的十年中，针对同源重组修复（Homologous Recombination Repair, HRR）缺陷肿瘤的治疗模式发生了根本性的变革。多聚ADP-核糖聚合酶（PARP）抑制剂的出现，通过“合成致死”（Synthetic Lethality）机制，为携带BRCA1/2突变或其他HRR缺陷的卵巢癌、乳腺癌、前列腺癌和胰腺癌患者提供了前所未有的生存获益 1。PARP酶家族包含17个成员，其中PARP1和PARP2在DNA单链断裂的碱基切除修复中发挥核心作用。当细胞受到DNA损伤时，PARP1会迅速结合到断裂位点并催化聚ADP-核糖基化（PARylation），从而招募其他修复蛋白 3。PARP抑制剂通过阻断这一过程，并在DNA复制过程中将PARP蛋白“捕获”（Trapping）在DNA链上，导致复制叉停滞和双链断裂。对于缺乏有效双链修复机制（即HRR缺陷）的肿瘤细胞而言，这种损伤是致命的 2。       然而，以奥拉帕利（Olaparib）、尼拉帕利（Niraparib）为代表的第一代PARP抑制剂在临床应用中面临着严峻的挑战，其核心痛点在于狭窄的治疗窗口和严重的脱靶毒性。研究表明，第一代药物对PARP1和PARP2具有几乎同等的抑制活性 5。虽然PARP1的抑制和捕获是驱动抗肿瘤药效的主要机制，但PARP2的抑制却被证实是导致严重血液学毒性（如贫血、中性粒细胞减少症和血小板减少症）的罪魁祸首，因为PARP2在红细胞生成和造血干细胞存活中扮演着不可或缺的角色 5。这种重叠的血液学毒性不仅经常迫使患者中断治疗或降低剂量——从而削弱了对PARP1的靶点占有率和抗肿瘤疗效——还极大地限制了第一代PARP抑制剂与其他骨髓抑制性药物（如标准化疗或抗体偶联药物ADC）的联合使用 2。 为了突破这一瓶颈，全球生物制药行业正大力推进下一代高选择性PARP1抑制剂的研发。这些新型药物旨在通过对PARP1的极高选择性（通常比对PARP2的选择性高数百倍），在保留甚至增强DNA捕获能力的同时，彻底剥离由PARP2介导的骨髓抑制毒性 4。本报告将深入剖析当前全球PARP1选择性抑制剂管线中两个备受瞩目却走向不同命运的案例：恒瑞医药HRS-1167（M9466）的跨国授权与战略退回，以及阿斯利康AZD5305（Saruparib）从早期概念验证到全球海量III期临床（EvoPAR项目）的突破性进展。 2. 商业版图的澄清：“默沙东”与“德国默克”在恒瑞管线中的不同角色       在深入探讨PARP1抑制剂的退回原因之前，必须对业界及公开查询中经常混淆的跨国药企实体进行严格的厘清。尽管外界常常将此次PARP1抑制剂的退回方误传为“默沙东”（MSD，即总部位于美国新泽西州罗威市的Merck & Co.），但大量的企业财务报告和官方声明证实，与恒瑞医药就PARP1抑制剂HRS-1167达成授权并随后终止合作的实体是德国默克（Merck KGaA，总部位于德国达姆施塔特）12。       这两家名称中均带有“默克”历史渊源的独立跨国巨头，在近两年内分别与恒瑞医药达成了完全不同的重大管线交易。为了准确评估全球制药市场的战略动向，以下表格清晰界定了这两笔交易的本质区别： 合作方 (跨国药企) 授权引进资产 药物靶点与适应症 交易时间与财务条款 当前状态与最新进展 默沙东 (MSD / Merck & Co.) HRS-5346 (MK-7262) Lp(a) 小分子抑制剂 (心血管代谢疾病) 2024-2025年；2亿美元首付款，高达17.7亿美元里程碑付款。 合作推进中。该资产已顺利整合入默沙东的心血管管线，补充了其在动脉粥样硬化领域的布局 16。 德国默克 (Merck KGaA) HRS-1167 (M9466)及SHR-A1904选择权 高选择性PARP1抑制剂 (晚期实体瘤) 及 Claudin 18.2 ADC 2023年10月；1.6亿欧元首付款，高达14亿欧元总潜在交易额 18。 已终止/退回。2026年第一季度，德国默克官方宣布基于组合疗法疗效和竞争格局终止该合作，恒瑞收回全球权益 12。      此外，默沙东（MSD）与恒瑞医药的交集还体现在监管审批层面。恒瑞医药的PD-1抑制剂卡瑞利珠单抗（camrelizumab）联合阿帕替尼（rivoceranib）在向美国FDA申报上市时，由于恒瑞苏州工厂的现场核查问题（涉及数据完整性和微生物污染防控等），收到了FDA的完整回应函（CRL），这在业内也引发了广泛关注 21。然而，这一监管受挫事件与PARP1抑制剂的授权退回是完全独立的商业与监管事件。本报告的后续分析将严格聚焦于德国默克（Merck KGaA）退回HRS-1167的战略动机。 3. 恒瑞医药HRS-1167（M9466）的全球化受挫：德国默克退货事件的深度复盘3.1 2023年超14亿欧元重磅交易的战略初衷        2023年10月，德国默克与恒瑞医药达成了一项震撼业界的战略授权协议。德国默克获得了恒瑞自主研发的下一代高选择性PARP1抑制剂HRS-1167（德国默克内部代号为M9466）在中国大陆以外的全球独家开发、生产和商业化权益，并获得了Claudin-18.2 ADC药物SHR-A1904的全球独家选择权 15。这笔交易的财务条款极为丰厚：恒瑞获得了1.6亿欧元的不可退还首付款，并有望获得最高达14亿欧元的研发与商业化里程碑付款及双位数比例的销售分成 18。 当时，德国默克的战略意图非常明确。该公司在其医疗保健业务中高度聚焦于DNA损伤应答（DDR）抑制剂和抗体偶联药物（ADC）的开发 15。HRS-1167在早期的I期临床单药试验中已经展示了令人鼓舞的抗肿瘤活性和良好的患者耐受性。德国默克的研发团队认为，由于HRS-1167特异性抑制PARP1而避开了PARP2，其差异化的安全性特征将完美契合德国默克宏大的“DDR通路联合阻断战略” 15。德国默克内部拥有共济失调毛细血管扩张及Rad3相关激酶（ATR）抑制剂tuvusertib（M1774）和ATM激酶抑制剂lartesertib。临床前模型假设，将高选择性PARP1抑制剂与ATR或ATM抑制剂联合使用，可以在不引发重叠性骨髓抑制毒性的前提下，彻底切断肿瘤细胞的DNA修复逃逸路径，从而攻克那些对第一代PARP抑制剂产生耐药性的难治性肿瘤 15。 3.2 联合疗法遭遇的临床瓶颈：DDRiver 501与PROCEADE-PanTumor研究的启示        然而，科学假设在严酷的临床试验中遭遇了滑铁卢。导致德国默克在2026年决定终止HRS-1167项目的最核心原因，在于其DDR组合疗法的临床数据未能达到预期的药效学阈值 20。        在达成授权后，德国默克迅速启动了包括PROCEADE-PanTumor和DDRiver 501（NCT06421935）在内的一系列Ib/II期多中心临床试验 24。这些矩阵式试验旨在评估M9466（HRS-1167）单药或与ATR抑制剂tuvusertib联合应用在既往接受过大量预处理（包括曾暴露于第一代PARP抑制剂）的晚期实体瘤（如去势抵抗性前列腺癌、卵巢癌和结直肠癌）患者中的安全性、耐受性与初步临床活性 24。        德国默克在2025年报及2026年初的官方声明中坦承，在一项针对既往有PARP抑制剂暴露史的卵巢癌患者的内部II期临床试验中，将DDR抑制剂（无论是泛PARP抑制剂尼拉帕利还是高选择性PARP1抑制剂M9466）与ATR抑制剂tuvusertib联合使用的方案，仅观察到了“令人失望的疗效信号”（underwhelming efficacy signal） 20。尽管这种DDR双重阻断并没有产生新的或不可控的安全信号（证明了PARP1选择性抑制剂在降低叠加毒性方面的确有优势），但其未能激发足够的协同抗肿瘤效应。由于无法在PARP耐药人群中产生突破性的治疗反应，德国默克被迫全盘否定了其基于ATR+PARP组合的管线拓展逻辑。这一战略误判直接导致德国默克计提了1200万欧元的无形资产减值准备，并决定全面停止相关组合的探索 20。 3.3 竞争格局的急剧恶化与德国默克的管线重组战略        除了临床疗效的不及预期，宏观的竞争格局演变与德国默克自身的财务压力也构成了退货的直接推手。在恒瑞与德国默克合作的短短两年间，高选择性PARP1抑制剂赛道已经从“蓝海”迅速变为“红海”。        如本报告第四部分将详细论述的，阿斯利康的AZD5305（Saruparib）在此期间以前所未有的速度推进了大规模的全球III期临床网络（EvoPAR项目），不仅在乳腺癌和前列腺癌领域确立了先发优势，更通过与新型内分泌药物（NHA）的联合展现了惊人的有效性 27。与此同时，辉瑞（Pfizer）的talazoparib正在TALAPRO-3试验中积极拓展早期前列腺癌适应症 30，而吉利德（Gilead/Artios）等其他竞争者也在紧追不舍 5。失去“ATR+PARP”组合这张底牌后，如果德国默克选择让HRS-1167重回单药路线或寻找其他联合用药方案，将面临比阿斯利康晚至少三到四年的上市时间差。在一个赢者通吃的精准靶向治疗市场，投资一项注定只能成为“Best-in-class”候选者却落后于“First-in-class”数年的巨额III期临床，显然违背了资本效率原则 14。         进一步的深层逻辑在于德国默克面临的管线系统性重组压力。根据2025年第四季度财报，德国默克的医疗保健业务正面临多发性硬化症口服重磅药物Mavenclad在北美市场遭遇仿制药竞争的巨大挑战 34。同时，其重金押注的IAP抑制剂Xevinapant在头颈癌的III期TrilynX研究中因未能达到主要终点而惨遭终止 33。在资金链与管线优先级的双重挤压下，德国默克进行了激烈的“管线清洗”，不仅退回了恒瑞的HRS-1167，还放弃了其耗资39亿美元收购SpringWorks Therapeutics所获得的多个临床阶段肿瘤管线（如Hippo通路抑制剂SW-682） 35。这些资本被重新分配至其认为胜算更高的ADC平台（如抗GD2 ADC M3554和抗CEACAM5 ADC M9140）上 20。 3.4 退货事件对恒瑞医药的财务与战略双重影响         对于恒瑞医药而言，此次HRS-1167被退回构成了一个复杂的战略节点。在财务层面，由于授权协议未设定强制退款条款，恒瑞医药已在2024年全额确认了1.6亿欧元（约合人民币12.3亿元）的无条件首付款收入 14。在全球资本寒冬和国内医保集采压价的大环境下，这笔巨额的非稀释性资金注入极大地充实了恒瑞的研发弹药库，支持了其在2025年前三季度高达49.45亿元的研发投入 13。         在资产层面，恒瑞重新获得了HRS-1167和SHR-A1904的全球完整权益。然而，挑战同样显而易见。目前，恒瑞医药在国内正试图通过独特的联合策略挖掘HRS-1167的价值，例如在NCT06516289临床试验中探索HRS-1167联合VEGFR抑制剂法米替尼（famitinib）在新辅助治疗gBRCA突变HER2阴性乳腺癌中的疗效 33。但在缺乏强大跨国合作方提供全球临床开发网络和资金支持的情况下，HRS-1167在欧美核心市场的商业化进程将不可避免地被大幅延缓。这一事件深刻反映了中国创新药企在出海过程中，资产价值的最终兑现高度依赖于跨国药企内部战略的稳定性与联合用药路径的科学可行性。 4. 阿斯利康AZD5305（Saruparib）：下一代PARP1抑制剂的破局者        与恒瑞HRS-1167因组合疗法受挫而退回的命运形成鲜明对比，阿斯利康的PARP1特异性抑制剂AZD5305（Saruparib）通过精准的临床试验设计和完全不同的联合用药逻辑，正在全面重塑晚期实体瘤的治疗标准。作为第一代泛PARP抑制剂奥拉帕利（Olaparib）的缔造者，阿斯利康深刻理解同类产品的毒性瓶颈，其开发AZD5305的战略核心是“自我革命与适应症升维”。 4.1 药物设计理念与临床前药效学特征       AZD5305在分子设计上实现了对PARP家族成员的极端分化选择。临床前药理学研究数据确证，AZD5305对PARP1的抑制和DNA捕获能力极强，而对PARP2的选择性比率高达500倍以上 4。在体内异种移植和PDX模型中，AZD5305展现出了比奥拉帕利更深度的肿瘤抑制作用和更持久的响应时间 4。 更重要的是大鼠毒理学模型的数据：在预测的临床有效暴露量下，AZD5305对网织红细胞、血小板和中性粒细胞等血液学参数的影响微乎其微 4。这种对造血系统的高度宽容，不仅从根本上证实了“靶向PARP1即可保留合成致死疗效，同时规避骨髓毒性”的科学假设，也为后续临床试验中挑战更高剂量的组合疗法铺平了道路。4.2 PETRA研究（Phase I/IIa）：确立最佳生物学剂量与单药有效性       AZD5305的临床验证始于极具前瞻性的PETRA试验（NCT04644068）。这是一项模块化、开放标签、多中心剂量递增和扩展研究，涵盖了携带HRR突变（BRCA1/2、PALB2、RAD51C/D等）的晚期乳腺癌、卵巢癌、前列腺癌和胰腺癌患者 6。 在2024年美国癌症研究协会（AACR）年会上公布的PETRA试验数据引发了业界的轰动，其最核心的贡献在于打破了传统的“最大耐受剂量（MTD）即最佳剂量”的临床范式。研究者发现，尽管AZD5305的MTD可达每日90mg，但每日60mg被确立为最佳生物学剂量 10。 在60mg剂量组的晚期HER2阴性乳腺癌患者中，AZD5305展现了惊人的疗效： 客观缓解率（ORR） 达到48.4%（80% CI, 35.7%-61.3%）。 中位缓解持续时间（DOR） 为7.3个月。 中位无进展生存期（PFS） 高达9.1个月 10。 同时，药物的安全性数据印证了临床前的优势。在整个PETRA研究中，因药物相关的治疗出现的不良事件（TEAE）导致的停药率极低。与第一代PARP抑制剂动辄超过30%-40%的重度贫血率相比，AZD5305导致的≥3级贫血和中性粒细胞减少症的发生率被大幅压缩（全剂量组≥3级贫血仅为14.8%，且在高剂量组未观察到严重恶化） 9。阿斯利康的首席研究员Timothy Yap博士指出，极低的剂量调整率意味着患者可以在最佳剂量下维持更长时间的治疗，从而实现对靶点的持续、深度占有（药代动力学分析显示靶点占有率超过90%），最大化长期生存获益 9。 4.3 PETRANHA研究：在转移性前列腺癌（mHSPC）中的突破性进展       如果说PETRA研究确立了AZD5305的单药地位，那么PETRANHA试验（NCT05367440）则展示了其在组合疗法上的巨大潜力，这也正是它与恒瑞HRS-1167命运分化的地方。        阿斯利康没有选择将AZD5305与同属DNA损伤修复（DDR）通路的ATR抑制剂联合（这已被证明会引发难以耐受的细胞毒性叠加），而是选择了机制上完全正交的“新型内分泌药物（NHA）”——即雄激素受体通路抑制剂（ARPI）。在晚期前列腺癌细胞中，PARP通路与雄激素受体（AR）信号转导网络之间存在紧密的相互作用；抑制AR会诱导类似于HRR缺陷的细胞表型（即诱导性合成致死），此时引入强效的PARP1抑制剂可以形成致命的交叉火力。        PETRANHA试验是一项多臂、非随机的I/IIa期研究，评估了AZD5305（每日60mg）联合恩扎卢胺（enzalutamide）、阿比特龙+泼尼松（abiraterone acetate）或达罗他胺（darolutamide）在转移性前列腺癌患者中的疗效与安全性 42。在2025年ESMO大会及2026年ASCO GU大会上公布的最新数据（数据截止日为2025年6月10日），震撼了泌尿肿瘤学界。        该队列纳入了93名转移性激素敏感性前列腺癌（mHSPC）患者，这些患者接受了AZD5305+ARPI+雄激素剥夺疗法（ADT）的三联治疗。以下表格详细展示了这项研究的突破性数据 27： 评估指标 全人群数据 (mHSPC队列) HRRm 突变亚组 Non-HRRm 无突变亚组 临床意义与解读 客观缓解率 (ORR) 82.4% (28/34) 100% (4/4) 85.7% (12/14) 极高的ORR证明了三重阻断的强效。尤为重要的是，在无基因突变（Non-HRRm）的患者中依然产生了85.7%的响应，这打破了PARP抑制剂仅适用于BRCA突变患者的传统认知，展现了泛人群治疗的潜力。 完全缓解率 (CR) 14.7% (5/34) 未单独披露 未单独披露 约15%的患者达到影像学上的病灶完全消失，显示出深度缓解能力。 确认的任意时间uPSA率 69.9% (65/93) 71.4% (10/14) 70.6% (24/34) 将近70%的患者实现了前列腺特异性抗原（PSA）检测不到（uPSA），这是预测长期生存的关键替代终点。 确认的52周uPSA率 76.7% (46/60) 77.8% (7/9) 73.9% (17/23) 高达四分之三的患者在一年后仍维持PSA检测不到，证明了疗效的极度持久性，且这种持久性在突变和非突变人群中保持高度一致。      在安全性方面，这种三联疗法的耐受性表现优异。最常见的治疗相关不良事件（TEAE）是贫血、疲劳、乏力和中性粒细胞减少症，但大多为低级别。因AZD5305导致的不良事件停药率仅为10.4%，且未观察到任何骨髓增生异常综合征（MDS）或急性髓系白血病（AML）的病例 43。这明确证明，剥离了PARP2的抑制作用后，AZD5305完全可以与现有的内分泌激素阻断疗法完美融合，实现了毒性不叠加而药效几何级放大的战略目标。5. 跨越晚期治疗：EvoPAR系列全球多中心III期临床项目全景解析        基于PETRA和PETRANHA中获得的无懈可击的数据，阿斯利康在过去的两年内以惊人的速度推进了名为"EvoPAR"的系列全球III期注册临床试验。该系列项目的宏大设计不仅旨在确立AZD5305作为“Best-in-class”的地位，更暴露了阿斯利康试图将PARP抑制剂的应用场景从后线推向前线、从晚期推向早期辅助治疗、从特定基因突变人群扩大至全人群的庞大野心。          目前，EvoPAR项目矩阵包含三大核心试验，累计计划入组超过3000名患者： 5.1 EvoPAR-Prostate01 (NCT06120491)：重塑转移性激素敏感性前列腺癌（mCSPC）的一线标准       这项随机、双盲、安慰剂对照的III期试验计划入组高达1800名mCSPC患者。试验设计最引人注目之处在于其设立了两个并行的队列：550名HRRm患者和1250名Non-HRRm（无突变）患者 45。患者以1:1的比例随机接受AZD5305联合新型内分泌药物（NHA：阿比特龙、达罗他胺或恩扎卢胺）或安慰剂联合NHA的治疗。主要终点为放射学无进展生存期（rPFS） 45。        阿斯利康投入巨资在1250名无突变患者中开展III期临床，是对PETRANHA试验中“非突变患者ORR达85.7%”这一数据的豪赌。一旦该队列达到rPFS的优效性终点（预计在2028年初进行主要数据分析）45，AZD5305将彻底摆脱基因检测的束缚，其目标市场规模将呈指数级扩大。 5.2 EvoPAR-Prostate02 (NCT06952803)：向早期高危局限性前列腺癌的辅助治疗进军       在2026年ASCO GU会议上详细介绍的EvoPAR-Prostate02试验，标志着AZD5305正式进入早期癌症的辅助治疗领域 47。该试验计划招募700名伴有BRCA1/2突变的局部高危/极高危前列腺癌患者，这些患者刚刚完成了根治性放疗（RT）且正在接受雄激素剥夺疗法（ADT） 48。        试验根据患者是否在ADT基础上联合使用了阿比特龙，分为队列A和队列B，各队列内以1:1随机分配至AZD5305组或安慰剂组，持续治疗24个月 47。该试验的主要终点被设定为无转移生存期（MFS），由中央盲态独立评估委员会（BICR）通过先进的临床成像技术（CT/MRI加骨扫描或PSMA PET）进行确认 47。在此阶段引入高安全性口服药物的目标在于清除可能存在的微小残留病灶（MRD），从而永久性延迟甚至防止生化复发，这将是前列腺癌治愈性治疗路径上的重大里程碑。该试验预计将于2033年完成初步数据收集 48。5.3 EvoPAR-Breast01 (NCT06380751)：挑战CDK4/6抑制剂的乳腺癌一线霸主地位         除了深耕前列腺癌，AZD5305也正在对乳腺癌的现有治疗标准发起猛烈冲击。EvoPAR-Breast01是一项开放标签的III期随机试验，计划纳入500名携带BRCA1、BRCA2或PALB2突变的激素受体阳性（HR+）且HER2阴性（IHC 0, 1+, 2+/ISH非扩增）的晚期乳腺癌一线治疗患者 28。         目前的标准一线疗法是CDK4/6抑制剂联合内分泌治疗。阿斯利康设计的试验包含三个对照臂：AZD5305联合其新一代口服选择性雌激素受体降解剂（SERD）Camizestrant，对比研究者选择的CDK4/6抑制剂联合标准内分泌治疗，或CDK4/6抑制剂联合Camizestrant 28。该试验直接对标辉瑞的哌柏西利（Palbociclib）、诺华的瑞波西利（Ribociclib）等CDK4/6抑制剂，试图证明在高危突变亚群中，高选择性PARP1抑制剂联合新型口服SERD能够提供比现有标准疗法更优的无进展生存期（PFS）。试验预计于2029年完成主要评估 29。 6. 全球PARP1抑制剂市场竞争格局与未来展望        随着我们步入2026年，全球制药行业正面临着历史上最严峻的“专利悬崖”（Patent Cliff）之一。从2025年到2030年，以默沙东的降糖药和免疫疗法、辉瑞的小分子药物为代表的一系列重磅炸弹药物即将失去市场独占期，仅美国市场预计就将蒸发超过2300亿美元的品牌药收入 52。在这一宏观背景下，各大型跨国药企对拥有长达十余年专利保护期、且具备“Pipeline-in-a-product”（单一产品即管线）潜力的下一代肿瘤靶向药物的争夺已进入白热化阶段。         阿斯利康通过AZD5305确立了在高选择性PARP1抑制剂领域的绝对领先地位。然而，竞争者并未停歇。辉瑞（Pfizer）正在通过TALAPRO-3试验积极拓展其第一代PARP抑制剂talazoparib在转移性激素敏感性前列腺癌中的早期应用 30；强生（J&J）则推出了基于尼拉帕利与阿比特龙的固定剂量复方制剂Akeega，试图通过依从性优势固守BRCA突变患者的市场份额 31。         更为前沿的研发趋势正在向“跨模态联合”演进。阿斯利康正在PETRA等早期试验中评估AZD5305与抗体偶联药物（ADCs）如Enhertu（德曲妥珠单抗，HER2 ADC）和Datroway（Dato-DXd，TROP2 ADC）的联合应用 6。ADC药物释放的细胞毒素载荷会导致DNA损伤，此时若同步施加无重叠骨髓毒性的PARP1抑制剂AZD5305，有望在多种缺乏HRR突变的实体瘤中人为制造脆弱性，将靶向治疗的边界拓展至前所未有的广度 6。 7. 结论与行业启示       回顾恒瑞医药HRS-1167与阿斯利康AZD5305的发展轨迹，高选择性PARP1抑制剂的演进历程深刻揭示了精准医疗领域药物开发的内在逻辑：分子结构的创新仅仅是入场券，真正决定药物商业与临床命运的，是与之匹配的科学联合策略。        通过切断对PARP2的抑制，新一代抑制剂成功去除了第一代药物伴随的严重血液学毒性枷锁。然而，德国默克在主导HRS-1167的开发时，执着于将其内部的ATR抑制剂（tuvusertib）与PARP抑制剂进行DDR通路内的双重阻断。这种机制上高度冗余的联合方式最终导致了临床获益的不及预期，叠加企业自身严峻的管线优化压力和迅速恶化的竞争环境，最终促成了这笔14亿欧元巨额授权的提前终止。        相反，阿斯利康凭借在DNA损伤应答领域深厚的底蕴，为AZD5305量身定制了与雄激素受体通路抑制剂（ARPI）和雌激素受体降解剂（SERD）等“正交机制”药物的联合方案。这种策略不仅完美保留了AZD5305在最佳生物学剂量下的强效PARP1捕获能力，更在PETRANHA试验中实现了跨越基因突变限制的惊人客观缓解率（ORR达82.4%）。随着涵盖超过3000名患者的EvoPAR全球III期项目的深入推进，AZD5305不仅有望彻底替代现有的第一代PARP抑制剂，更极有可能在未来数年内重写乳腺癌与前列腺癌的一线及辅助治疗国际指南。Works cited Ovarian cancer drug pipeline: PARP inhibitors and ADCs - PatSnap, accessed April 18, 2026, https://www.patsnap.com/resources/blog/articles/ovarian-cancer-drug-pipeline-parp-inhibitors-and-adcs/ Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305 - Frontiers, accessed April 18, 2026, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.979873/full PARP1-Selective Inhibitors Generate Excitement in Solid Tumors | OncLive, accessed April 18, 2026, https://www.onclive.com/view/parp1-selective-inhibitors-generate-excitement-in-solid-tumors Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper - PMC, accessed April 18, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9623235/ Merck pays $169M for selective PARP1 drug, stepping up challenge to AstraZeneca and Gilead - Fierce Biotech, accessed April 18, 2026, https://www.fiercebiotech.com/biotech/merck-pays-169m-selective-parp1-drug-stepping-challenge-astrazeneca-and-gilead Selective PARP1 Inhibitor Shows Activity, Safety in Early-Stage Trial, accessed April 18, 2026, https://www.oncologynewscentral.com/conference-news/selective-parp1-inhibitor-shows-activity-safety-in-early-stage-trial Next-Generation PARP1-Selective Inhibitor Offers Significant Benefits Over Older Predecessors in Treatment of Solid Tumors - The ASCO Post, accessed April 18, 2026, https://ascopost.com/issues/may-25-2022/parp1-selective-inhibitor-offers-significant-benefits-over-older-predecessors-in-treatment-of-solid-tumors/ Advances in Development of Selective Antitumor Inhibitors That Target PARP-1 | Journal of Medicinal Chemistry - ACS Publications, accessed April 18, 2026, https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c00865 Next-generation PARP Inhibitor Demonstrates Clinical Benefit in Patients with Homologous Recombination Repair-deficient Breast Cancer | News Releases | AACR, accessed April 18, 2026, https://www.aacr.org/about-the-aacr/newsroom/news-releases/next-generation-parp-inhibitor-demonstrates-clinical-benefit-in-patients-with-homologous-recombination-repair-deficient-breast-cancer/ First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors | OncLive, accessed April 18, 2026, https://www.onclive.com/view/first-in-class-parp1-selective-inhibitor-saruparib-shines-in-phase-1-trial-of-advanced-solid-tumors FDA撤销适应症，PARP下一步该怎么走？ - 中国医药创新促进会, accessed April 18, 2026, https://www.phirda.com/artilce_31287.html?module=trackingCodeGenerator 默克终止与恒瑞14亿欧元合作 - 医药魔方, accessed April 18, 2026, https://www.pharmcube.com/newsLibrary/detail?id=33cb9c4f14a8648dc1663bd26993952f 默克果断止损，恒瑞医药14亿欧元合作告吹 - 新浪财经, accessed April 18, 2026, https://finance.sina.com.cn/stock/stockzmt/2026-03-21/doc-inhrtucv9891522.shtml 恒瑞醫藥 - HKEXnews, accessed April 18, 2026, https://www.hkexnews.hk/listedco/listconews/sehk/2026/0326/2026032600033.pdf Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui, accessed April 18, 2026, https://www.merckgroup.com/en/news/hengrui-oncology-collab-30-10-2023.html MSD Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd., accessed April 18, 2026, https://www.msd.com/news/msd-enters-exclusive-license-agreement-for-hrs-5346-an-investigational-oral-lipoproteina-inhibitor-for-cardiovascular-disease-from-jiangsu-hengrui-pharmaceuticals-co-ltd/ Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd., accessed April 18, 2026, https://www.merck.com/news/merck-enters-exclusive-license-agreement-for-hrs-5346-an-investigational-oral-lipoproteina-inhibitor-for-cardiovascular-disease-from-jiangsu-hengrui-pharmaceuticals-co-ltd/ Merck signs €1.4bn cancer alliance with China's Hengrui - pharmaphorum, accessed April 18, 2026, https://pharmaphorum.com/news/merck-signs-eu14bn-cancer-alliance-chinas-hengrui Hengrui Pharma Partners with Merck KGaA, Darmstadt, Germany, to Advance Innovative Cancer Therapies - PR Newswire, accessed April 18, 2026, https://www.prnewswire.com/news-releases/hengrui-pharma-partners-with-merck-kgaa-darmstadt-germany-to-advance-innovative-cancer-therapies-301970919.html Annual Report - Merck Group, accessed April 18, 2026, https://www.merckgroup.com/content/dam/web/corporate/non-images/press-kits/q4-2025/en/2025-Q4-Report-EN.pdf FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again - Fierce Pharma, accessed April 18, 2026, https://www.fiercepharma.com/pharma/fda-rejects-hengrui-elevars-pd-1-cancer-drug-combination-again Behind Hengrui's surprise FDA rejection: Scathing Form 483 lists litany of shortfalls at PD-1 drug plant - Fierce Pharma, accessed April 18, 2026, https://www.fiercepharma.com/manufacturing/behind-fda-rejection-scathing-form-483-hengrui-pd-1-plant-counts-litany-shortfalls News Release Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next- Generation Selective PARP1, accessed April 18, 2026, https://www.merckgroup.com/content/dam/web/corporate/non-images/press-releases/2023/oct/en/Hengrui-Oncology-Collaboration-EN.pdf M9466 as Single Agent or in Combination With Tuvusertib in Advanced Solid Tumors DDRiver 501 (NCT06421935) | CareAcross Lung Cancer service, accessed April 18, 2026, https://www.careacross.com/clinical-trials/trial/NCT06421935 Merck's Innovative Oncology Pipeline of DDRi and ADC Poised to Advance Cancer Treatment, accessed April 18, 2026, https://www.merckgroup.com/en/news/oncology-update-03-06-2024.html M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) - Merck Clinical Trials, accessed April 18, 2026, https://clinicaltrials.merckgroup.com/en/trial-details/?id=MS202659_0001 Saruparib + androgen receptor pathway inhibitor (ARPI) + androgen deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): The phase 1/2 PETRANHA trial. - ASCO Publications, accessed April 18, 2026, https://ascopubs.org/doi/10.1200/JCO.2026.44.7_suppl.177 Clinical Trials Appendix - FY 2025 Results Update - AstraZeneca, accessed April 18, 2026, https://www.astrazeneca.com/content/dam/az/PDF/2025/Q4-FY/Full-year-Q4-2025-clinical-trial-appendix.pdf Saruparib (AZD5305) plus Camizestrant compared with CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer - EvoPAR-BR01 - AstraZeneca Clinical Trials, accessed April 18, 2026, https://www.astrazenecaclinicaltrials.com/study/D9722C00001/ Pfizer aims for wider use of PARP drug in prostate cancer with new data | BioPharma Dive, accessed April 18, 2026, https://www.biopharmadive.com/news/pfizer-talzenna-prostate-parp-early-talapro-study-results/815180/ Pfizer bags a hormone-sensitive win | ApexOnco - Clinical Trials news and analysis, accessed April 18, 2026, https://www.oncologypipeline.com/apexonco/pfizer-bags-hormone-sensitive-win PARP Inhibitor Market Size, Forecast, Outlook, Companies - DelveInsight, accessed April 18, 2026, https://www.delveinsight.com/report-store/parp-inhibitors-competitive-landscape-pipeline-and-market-analysis 默克“退货”恒瑞医药：14亿欧元BD终止 - 财富号, accessed April 18, 2026, https://caifuhao.eastmoney.com/news/20260311093609236054900 Earnings call transcript: Merck KGaA's Q4 2025 results show resilience amid FX headwinds, accessed April 18, 2026, https://www.investing.com/news/transcripts/earnings-call-transcript-merck-kgaas-q4-2025-results-show-resilience-amid-fx-headwinds-93CH-4543188 Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal, accessed April 18, 2026, https://www.fiercebiotech.com/biotech/merck-kgaa-ending-pursuit-remaining-assets-39b-springworks-buyout Merck KGaA abandons Phase III trial for $1.08bn head & neck cancer drug, accessed April 18, 2026, https://www.clinicaltrialsarena.com/news/merck-kgaa-abandons-phase-iii-trial-for-1-08bn-head-neck-cancer-drug/ Study Details | NCT06516289 | Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab | ClinicalTrials.gov, accessed April 18, 2026, https://clinicaltrials.gov/study/NCT06516289 The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models - PMC, accessed April 18, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11348616/ Next-Gen PARP Inhibitor Effective in Breast Cancer - AACR Journals, accessed April 18, 2026, https://aacrjournals.org/cdnews/news/1409/Next-Gen-PARP-Inhibitor-Effective-in-Breast-Cancer AZD5305 Yields Promising Clinical and Safety Findings Across Several Solid Malignancies, accessed April 18, 2026, https://www.cancernetwork.com/view/azd5305-yields-promising-clinical-and-safety-findings-across-several-solid-malignancies AACR 2022: Next-generation PARP1-selective inhibitor demonstrates promising clinical activity with a favourable safety profile - ecancer, accessed April 18, 2026, https://ecancer.org/en/news/21761-aacr-2022-next-generation-parp1-selective-inhibitor-demonstrates-promising-clinical-activity-with-a-favourable-safety-profile PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results. - ASCO, accessed April 18, 2026, https://www.asco.org/abstracts-presentations/230047 ESMO 2025: First Interim Efficacy Analysis of the Phase 1/2 PETRANHA Trial of Saruparib + Androgen Receptor Pathway Inhibitors (ARPI) in Patients (Pts) with Metastatic Prostate Cancer (mPC) - UroToday, accessed April 18, 2026, https://www.urotoday.com/conference-highlights/esmo-2025/esmo-2025-prostate-cancer/164003-esmo-2025-first-interim-efficacy-analysis-of-the-phase-1-2-petranha-trial-of-saruparib-androgen-receptor-pathway-inhibitors-arpi-in-patients-pts-with-metastatic-prostate-cancer-mpc.html ASCO GU 2026: Saruparib + ARPI + ADT in Patients with mHSPC: The Phase 1/2 PETRANHA Trial - UroToday, accessed April 18, 2026, https://www.urotoday.com/conference-highlights/asco-gu-2026/asco-gu-2026-prostate-cancer/166879-asco-gu-2026-saruparib-arpi-adt-in-patients-with-mhspc-the-phase-1-2-petranha-trial.html Saruparib (AZD5305) vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents - EvoPAR-PR01 - AstraZeneca Clinical Trials, accessed April 18, 2026, https://www.astrazenecaclinicaltrials.com/study/D9723C00001/ Study Details | NCT06120491 | Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | ClinicalTrials.gov, accessed April 18, 2026, https://clinicaltrials.gov/study/NCT06120491 ASCO GU 2026: EvoPAR-Prostate02: Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Adjuvant Saruparib (AZD5305) in Patients with BRCA Mutated Localized High-Risk Prostate Cancer Who Are Receiving Radiotherapy and ADT - UroToday, accessed April 18, 2026, https://www.urotoday.com/conference-highlights/asco-gu-2026/asco-gu-2026-prostate-cancer/166916-asco-gu-2026-evopar-prostate02-phase-iii-randomized-double-blind-placebo-controlled-study-of-adjuvant-saruparib-azd5305-in-patients-with-brca-mutated-localized-high-risk-prostate-cancer-who-are-receiving-radiotherapy-and-adt.html NCT06952803 | A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | ClinicalTrials.gov, accessed April 18, 2026, https://clinicaltrials.gov/study/NCT06952803 A study of metastases free survival with Saruparib vs placebo added to a standard RT/ADT in men with high-risk prostate cancer with a BRCA mutation - EvoPAR-PR02 - AstraZeneca Clinical Trials, accessed April 18, 2026, https://www.astrazenecaclinicaltrials.com/study/D9727C00001/ Phase III, randomized, double-blind, placebo-controlled study of adjuvant saruparib (AZD5305) in patients with BRCAm localized high-risk prostate cancer who are receiving radiotherapy and androgen deprivation therapy (EvoPAR-Prostate02). | Journal of Clinical Oncology - ASCO Publications, accessed April 18, 2026, https://ascopubs.org/doi/10.1200/JCO.2026.44.7_suppl.TPS412 EvoPAR-BR01: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer - AstraZeneca Breast Cancer Study Locator, accessed April 18, 2026, https://www.breastcancerstudylocator.com/trial/listing/479895 Blockbuster drugs face a massive patent cliff in 2026 - Drug Discovery News, accessed April 18, 2026, https://www.drugdiscoverynews.com/blockbuster-drugs-face-a-massive-patent-cliff-in-2026-17019 AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO, accessed April 18, 2026, https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-furthers-ambition-to-redefine-cancer-care-with-first-data-from-four-major-pivotal-trials-at-esmo.html